NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

NVO chart

Key facts today

Novo Nordisk's 2025 sales outlook is under review due to weak U.S. prescription data for Wegovy, raising doubts about projected 16% to 24% growth ahead of May 7 results.

A U.S. judge denied compounding pharmacies' request to produce Novo Nordisk's Ozempic and Wegovy, enforcing an FDA deadline for larger facilities to exit by May 22, 2025.

Novo Nordisk (NOVO-B) has partnered with Lifera to produce semaglutide therapies for weight management in Saudi Arabia, aiming to launch the obesity drug Wegovy by 2025.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.